Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

5.2K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
5.2K
Abnormal Proliferation02:23

Abnormal Proliferation

5.0K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

1.8K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.5K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Covalently Linked Protein Regulators02:04

Covalently Linked Protein Regulators

8.5K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
8.5K
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

5.7K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
5.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Needle-track metastasis in diffuse intrinsic pontine glioma: Need for a standardized surgical strategy?

Neuro-oncology advances·2026
Same author

Incidence and Risk Factors of Symptomatic Osteonecrosis in Children With Acute Lymphoblastic Leukemia-A Population-Based Analysis of the Austrian ALL-BFM Study Group.

EJHaem·2026
Same author

Incomplete tumor resection, central neuroradiological review, and second surgery in pediatric patients with intracranial ependymoma treated in the E-HIT2000 trial.

Journal of neurosurgery. Pediatrics·2026
Same author

Preterm Noonan syndrome with generalised venolymphatic malformation.

Archives of disease in childhood. Fetal and neonatal edition·2026
Same author

The HIT Network for Children and Adolescents With CNS Tumors Facilitates Improvements of Diagnostic Assessments, Multimodal Treatments, Individual Counseling, and Research in Germany, Austria, and Switzerland.

Pediatric blood & cancer·2026
Same author

Pediatric high-grade gliomas in patients with neurofibromatosis type 1-A collaborative cohort study from the SIOPE HGG/DIPG working group.

Neuro-oncology practice·2026
Same journal

An IL-15 fusion with albumin-binding domain boosts Immunotherapy therapy in glioblastoma via FGF-2 competition regulating FGFR1/2.

Cancer letters·2026
Same journal

Stress-adapted cancer-associated fibroblasts as mediators of immunosuppression and therapy resistance.

Cancer letters·2026
Same journal

Aldo-keto Reductase Family 1 Member C3 Suppresses Glioma Progression via Inhibiting Prostaglandin D2-Dependent RhoA/ROCK Signaling.

Cancer letters·2026
Same journal

Immunotherapy-based combination remodels the immunosuppressive microenvironment and enhances efficacy in advanced SMARCA4-deficient non-small cell lung cancer.

Cancer letters·2026
Same journal

Early-onset lung cancer: etiologic heterogeneity, genomic features, and age-informed clinical management.

Cancer letters·2026
Same journal

Talazoparib engages innate immune activation via PARP trapping-dependent cGAS/STING activation in Ewing Sarcoma.

Cancer letters·2026
See all related articles

Related Experiment Video

Updated: Dec 23, 2025

SUMO-Binding Entities SUBEs as Tools for the Enrichment, Isolation, Identification, and Characterization of the SUMO Proteome in Liver Cancer
08:29

SUMO-Binding Entities SUBEs as Tools for the Enrichment, Isolation, Identification, and Characterization of the SUMO Proteome in Liver Cancer

Published on: November 1, 2019

7.5K

SUMOylation in carcinogenesis.

Kira Bettermann1, Martin Benesch, Serge Weis

  • 1Institute of Pathology, Medical University of Graz, Austria.

Cancer Letters
|December 6, 2011
PubMed
Summary
This summary is machine-generated.

SUMOylation, a key protein modification, is increasingly linked to cancer development. This review explores SUMOylation

More Related Videos

In Vitro SUMOylation Assay to Study SUMO E3 Ligase Activity
09:45

In Vitro SUMOylation Assay to Study SUMO E3 Ligase Activity

Published on: January 29, 2018

9.6K
In Vivo Detection and Analysis of Rb Protein SUMOylation in Human Cells
09:40

In Vivo Detection and Analysis of Rb Protein SUMOylation in Human Cells

Published on: November 2, 2017

7.6K

Related Experiment Videos

Last Updated: Dec 23, 2025

SUMO-Binding Entities SUBEs as Tools for the Enrichment, Isolation, Identification, and Characterization of the SUMO Proteome in Liver Cancer
08:29

SUMO-Binding Entities SUBEs as Tools for the Enrichment, Isolation, Identification, and Characterization of the SUMO Proteome in Liver Cancer

Published on: November 1, 2019

7.5K
In Vitro SUMOylation Assay to Study SUMO E3 Ligase Activity
09:45

In Vitro SUMOylation Assay to Study SUMO E3 Ligase Activity

Published on: January 29, 2018

9.6K
In Vivo Detection and Analysis of Rb Protein SUMOylation in Human Cells
09:40

In Vivo Detection and Analysis of Rb Protein SUMOylation in Human Cells

Published on: November 2, 2017

7.6K

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • SUMOylation is a reversible post-translational modification involving small ubiquitin-like modifiers (SUMO).
  • SUMO proteins regulate nuclear organization and cell viability.
  • SUMOylation is upregulated in processes like cell growth, differentiation, senescence, oxidative stress, and apoptosis, all linked to cancer.

Purpose of the Study:

  • To review the implications of SUMOylation in carcinogenesis.
  • To highlight SUMOylation's role as a cell cycle regulator in cancer.
  • To discuss novel therapeutic strategies targeting SUMOylation.

Main Methods:

  • Literature review of studies on SUMOylation and cancer.
  • Analysis of SUMOylation's impact on cell cycle regulation.
  • Exploration of therapeutic targets within the SUMO pathway.

Main Results:

  • SUMOylation plays a significant role in various stages of carcinogenesis.
  • SUMOylation impacts cell cycle regulation, influencing cancer progression.
  • Differential SUMOylation patterns across cancer subtypes present complex challenges.

Conclusions:

  • SUMOylation is a critical factor in cancer development and progression.
  • Targeting SUMOylation offers potential for novel cancer therapies.
  • Further research is needed to fully elucidate SUMOylation's complex role in diverse cancers.